Novo Nordisk signs $3.3bn deal to acquire Dicerna Pharmaceuticals
Novo Nordisk has signed a deal worth around $3.3 billion to acquire Dicerna Pharmaceuticals, a US-based biotech company focused on developing ribonucleic acid interference (RNAi) ... Read More
Alnylam, Dicerna form RNAi collaboration for alpha-1 liver disease
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are joining forces to develop and commercialize ribonucleicacid interference therapies (RNAi therapeutics) for the treatment of alpha-1 antitrypsin deficiency-associated liver ... Read More
Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies
Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B ... Read More